Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.

There was a concerning development in the company's clinical trials. Shares of Verve Therapeutics (VERV 1.28%) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence.

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday.

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.